“Does CERC-501 Attenuate Stress-Related Smoking Lapse?” The study is a collaborative effort between Cerecor and Dr. McKee and is supported by funding from the National Institutes of Health (NIH). “Stress is a primary contributor to the maintenance of, and
The post Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers appeared first on The Center.
August 29, 2016 at 11:06AM
No comments:
Post a Comment